News Releases
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California
April 22, 2024
Vancouver, British Columbia, April 22, 2024 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April. Cannabix’s Dr. Bruce Goldberger Ph.D., will be presenting on Science & Technology Behind Cannabis Breath Testing and the Company’s marijuana breathalyzer system at the conference workshop session. IACT is composed of governmental agency personnel involved in chemical testing related to traffic safety. IACT members are scientific and criminal justice professionals, including forensic scientists, regulatory inspectors, and law enforcement personnel with representatives from a majority of states and international members. IACT has standing committees to address various areas including legislation, training, new equipment and procedures and manufacturers of breath testing equipment.
The Cannabis Breath Testing workshop at IACT 2024 is designed to provide background information regarding the pharmacokinetics and pharmacodynamics of cannabinoids in breath, present the current technology for collection devices from commercial vendors, and discuss the necessary laboratory workflows and analytical considerations when testing these samples.
Dr. Bruce Goldberger is a professor and the former Chief of the Forensic Medicine Division in the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida. Dr. Goldberger served as Director of the University of Florida forensic toxicology laboratory for 30 years. Dr. Goldberger is the Principal Investigator of the Florida Drug-Related Outcomes Surveillance and Tracking System and Co-investigator of the National Drug Early Warning System. Dr. Goldberger is a consultant for the Centers for Disease Control and Prevention’s National Center for Injury Prevention and Control, Overdose Mortality Team, and the National Center for Health Statistics, Division of Vital Statistics. Dr. Goldberger is a consultant and senior advisor to Cannabix Technologies Inc.
Disclaimer:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
